These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 4093687)

  • 1. [Experimental study for active specific immunotherapy and immunochemotherapy using 3M KC1 solubilized tumor].
    Kobayashi M
    Nihon Gan Chiryo Gakkai Shi; 1985 Oct; 20(9):2112-25. PubMed ID: 4093687
    [No Abstract]   [Full Text] [Related]  

  • 2. [Specific active immunotherapy of murine methylcholanthrene-induced sarcoma using a partially purified soluble tumor specific transplantation antigens].
    Tanaka T; Yamagishi H; Inaba S; Kobayashi M; Kurioka H; Naito K; Hashimoto I
    Nihon Geka Gakkai Zasshi; 1983 Apr; 84(4):282-94. PubMed ID: 6201713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
    Simmons RL; Rios A
    Johns Hopkins Med J Suppl; 1974; 3():75-84. PubMed ID: 4536589
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific rejection and regression of solid tumour by tumour extract.
    Menon IR; Batra BK; Raveendran P
    Indian J Med Res; 1974 Jul; 62(7):1032-8. PubMed ID: 4435913
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. II. Rejection of tumour graft 'in vivo' humoral and lymphocytotoxicity 'in vitro'.
    Bendre AR; Gangal SG
    Indian J Cancer; 1978 Dec; 15(4):9-16. PubMed ID: 757692
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Vaccinia virus as an adjuvant in inducing specific anti-tumour immunity to transplantable mouse fibrosarcoma. I. Adaptation of the virus to mouse tumour cells as a pre-requisit for adjuvanticity.
    Bendre AR; Gangal SG
    Indian J Cancer; 1978 Dec; 15(4):1-8. PubMed ID: 757683
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
    Simmons RL; Rios A; Lundgren G; Ray PK; McKhann CF; Haywood GR
    Surgery; 1971 Jul; 70(1):38-46. PubMed ID: 5092115
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of modified tumor antigen on experimentally induced sarcomas.
    Nigam SK; Bhatt VH
    Saudi Med J; 2001 Feb; 22(2):157-63. PubMed ID: 11299413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of local immunotherapy of syngeneic rat fibrosarcoma with hapten and antihapten-tumor serum upon nonlocally treated tumor.
    Arai K; Wallace HW
    Cancer Res; 1979 Sep; 39(9):3638-43. PubMed ID: 314334
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
    Kahan BD; Tanaka T; Pellis NR
    J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Augmentation of specific anti-tumor immunity by immunization with xenogenized tumor cells and its application to the experimental cancer treatment (author's transl)].
    Okayasu T
    Hokkaido Igaku Zasshi; 1981 Nov; 56(6):615-22. PubMed ID: 7338338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.
    Vaage J
    Cancer Res; 1971 Nov; 31(11):1655-62. PubMed ID: 5121668
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of antitumor immunity--immunobiologic approaches.
    North RJ; Dye ES; Mills CD; Chandler JP
    Springer Semin Immunopathol; 1982; 5(2):193-220. PubMed ID: 6293113
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of adherent cells in tumor immunity.
    Burk MW; Yu S; McKhann CF
    Surg Forum; 1975; 26():140-2. PubMed ID: 1216090
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of regional lymphadenectomy on development of concomitant immunity.
    Soloway MS; Pendergrast WJ; Myers GH
    Surg Forum; 1972; 23(0):101-2. PubMed ID: 4671039
    [No Abstract]   [Full Text] [Related]  

  • 16. The soluble antigens of BALB/c sarcoma Meth-A: a relationship between a serologically defined tumor-specific surface antigen (TSSA) and the tumor-associated transplantation antigen (TATA).
    DuBois GC; Appella E; Law LW; DeLeo AB; Old LJ
    Transplant Proc; 1981 Dec; 13(4):1765-73. PubMed ID: 6173944
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
    Liotta LA; Kleinerman J; Saidel GM
    Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of the tumor rejection antigen of Rous sarcoma virus-induced murine fibrosarcoma.
    Suda T; Shimizu J; Mizushima Y; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1988 Mar; 79(3):365-74. PubMed ID: 2453498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal tissue antigens of tumor cells.
    Milas L; Suit HD
    Tex Rep Biol Med; 1969; 27(2):467-9. PubMed ID: 4900374
    [No Abstract]   [Full Text] [Related]  

  • 20. [The immunotherapeutic effect of partially purified tumor specific transplantation antigen against pulmonary metastasis].
    Inaba S; Tanaka T; Yamagishi H; Kobayashi M; Tsuchiya K; Oka T
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2273-8. PubMed ID: 6533208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.